Innovating Next-Generation ADC Constructs

In this segment from the Bioprocess Online Live event “Evolving CMC Strategies To Enable Next-Gen ADCs,” panelists Michael Torres, Ph.D. (CrossBridge Bio), Morris Rosenberg, Ph.D. (CrossBridge Bio), and Borys Shor, Ph.D. (OS Therapies and Manhattan BioSolutions) share their thoughts on what constitutes a next-generation ADC and discuss innovations in the space, particularly in linkers, payloads, and consistent molecular homogeneity with respect to drug-antibody ratio (DAR).